TY - JOUR

T1 - Water-soluble hybrids LaVO4:Eu3+@diamine phosphine with photoswitchable butyrylcholinesterase inhibition and luminescent imaging

AU - Колесников, Илья Евгеньевич

AU - Бикбаева, Гулия Ильнуровна

AU - Егорова, Анастасия Валерьевна

AU - Пилип, Анна Георгиевна

AU - Медведев, Василий Андреевич

AU - Мамонова, Дарья Владимировна

AU - Панькин, Дмитрий Васильевич

AU - Калиничев, Алексей Андреевич

AU - Маячкина, Наталья Викторовна

AU - Бакина, Людмила Георгиевна

AU - Маньшина, Алина Анвяровна

PY - 2025/11

Y1 - 2025/11

N2 - We report a water-soluble hybrid nanosystem that combines luminescence LaVO4:Eu3+ (LEu) nanoparticles with a photoswitchable and bioactive diamine phosphine oxide (DP) shell for light-activated medical treatment. While existing photopharmacological agents often face challenges with water solubility and real-time tracking, our design integrates imaging and photoswitchable therapeutic functions in a single platform. The synthesized hybrids were thoroughly characterized by a wide set of experimental techniques, including NMR, Raman, XRD, and optical spectroscopy. Remarkably, the hybrid maintains strong Eu3+ emission (5D0–7F2 transition at 613 nm), which is affected by laser irradiation. Biological studies revealed a three-fold enhancement in butyrylcholinesterase inhibition efficiency (20 %–60 %) after laser irradiation, surpassing the performance of free DP (two-fold enhancement under the same conditions). In vivo evaluation using Daphnia magna demonstrated excellent biocompatibility and selective accumulation in the digestive system, with clearly distinguishable Eu3+ luminescence against tissue autofluorescence. This work advances photopharmacology by providing a robust strategy for developing image-guided, light-responsive therapies with high precision and efficacy.

AB - We report a water-soluble hybrid nanosystem that combines luminescence LaVO4:Eu3+ (LEu) nanoparticles with a photoswitchable and bioactive diamine phosphine oxide (DP) shell for light-activated medical treatment. While existing photopharmacological agents often face challenges with water solubility and real-time tracking, our design integrates imaging and photoswitchable therapeutic functions in a single platform. The synthesized hybrids were thoroughly characterized by a wide set of experimental techniques, including NMR, Raman, XRD, and optical spectroscopy. Remarkably, the hybrid maintains strong Eu3+ emission (5D0–7F2 transition at 613 nm), which is affected by laser irradiation. Biological studies revealed a three-fold enhancement in butyrylcholinesterase inhibition efficiency (20 %–60 %) after laser irradiation, surpassing the performance of free DP (two-fold enhancement under the same conditions). In vivo evaluation using Daphnia magna demonstrated excellent biocompatibility and selective accumulation in the digestive system, with clearly distinguishable Eu3+ luminescence against tissue autofluorescence. This work advances photopharmacology by providing a robust strategy for developing image-guided, light-responsive therapies with high precision and efficacy.

KW - Butyrylcholinesterase inhibition

KW - Luminescent imaging

KW - Water-soluble hybrids

UR - https://www.mendeley.com/catalogue/d8580050-2ae7-3547-8e65-ccb5cb9c3949/

U2 - 10.1016/j.optmat.2025.117522

DO - 10.1016/j.optmat.2025.117522

M3 - Article

VL - 168

JO - Optical Materials

JF - Optical Materials

SN - 0925-3467

M1 - 117522

ER -